Key findings

  • 53 eyesof 42 patients in Nigeria whose IOP was not adequately controlled with medication were treated with frequency-doubled Nd:YAG 532-nm laser trabeculoplasty
  • 31.70%mean reduction in IOP, from 18.59 to 11.55 mmHg (P < 0.001)
  • 27 of 30eyes with a pre-treatment IOP of 18 mmHg or higher were brought below the 18 mmHg target (90.0%)
  • 45.3%of eyes had their medications reduced and 20.8% had them increased; the overall change in medication number was not statistically significant

Abstract

Aim
To evaluate the efficacy of frequency-doubled Nd:YAG 532-nm laser trabeculoplasty in reducing intraocular pressure (IOP) and antiglaucoma medication requirements in Nigerian patients with glaucoma.
Methods
This retrospective, non-comparative interventional case series included patients who underwent frequency-doubled Nd:YAG 532-nm laser trabeculoplasty. Demographic characteristics, ocular history, anterior chamber angle status, visual acuity, IOP, antiglaucoma medications, and treatment parameters were retrieved from hospital case records. IOP, visual acuity, and medication requirements were assessed before treatment and during follow-up.
Results
The study included 53 eyes of 42 patients. Before laser treatment, 56.6% of eyes had an IOP ≥18 mmHg, compared with 94.3% having an IOP <18 mmHg following trabeculoplasty. Mean IOP was 12.3 ± 3.1 mmHg at 1 month, 11.9 ± 2.3 mmHg at 6 months, 12.2 ± 2.5 mmHg at 12 months, 12.7 ± 3.0 mmHg at 18 months, 11.2 ± 2.5 mmHg at 24 months, 12.5 ± 6.2 mmHg at 30 months, and 12.3 ± 7.5 mmHg at 36 months. The mean percentage IOP reduction was 31.70% SD 24.90 (p=0.0002). Visual acuity improved significantly following treatment (p=0.0001). Medication requirements decreased in 24 eyes (45.3%), remained unchanged in 17 (32.1%), and increased in 11 (20.8%); one eye (1.9%) required no medication before or after treatment.
Conclusion
Frequency-doubled Nd:YAG 532-nm laser trabeculoplasty achieved substantial and sustained IOP reduction over 36 months. It may provide an effective adjunctive and medication-sparing treatment option for selected Nigerian patients with open-angle glaucoma and may help delay the need for incisional surgery.

Introduction

Glaucoma is the second leading cause of blindness worldwide, affecting tens of millions of people globally.1,2 It affects all age groups, both sexes, racial and ethnic groups. However, the burden of glaucoma is disproportionately greater among people of African descent, who tend to develop the disease at a younger age and experience more severe and rapidly progressive disease.3–5 Advanced glaucoma can significantly impair visual function and quality of life, with profound social, psychological, and economic consequences for affected individuals, their families, and healthcare systems.6

The Nigerian National Blindness and Visual Impairment Survey, conducted between 2005 and 2007, demonstrated that glaucoma accounted for approximately 16.7% of blindness among adults aged ≥40 years, making it the second leading cause of blindness after cataract and the leading cause of irreversible blindness in Nigeria.7 Given the irreversible nature of glaucomatous optic neuropathy and the high proportion of affected individuals who remain undiagnosed, glaucoma represents a major public health challenge in Nigeria.8

Elevated intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma and remains the principal therapeutic target in glaucoma management. Although the relationship between IOP and glaucomatous damage is well established, the relative contributions of peak IOP, mean IOP, and IOP fluctuation to retinal ganglion cell and optic nerve damage remain incompletely defined. Evidence suggests that the overall level of IOP, particularly sustained or higher mean IOP, is strongly associated with disease progression, whereas the independent contribution of short-term IOP fluctuations is less certain. Indeed, recent evidence indicates that IOP fluctuation may have limited correlation with visual-field progression after adjustment for mean IOP.9

Consequently, the principal aim of IOP-lowering therapy is to achieve and maintain an individualized target IOP that is sufficiently low to reduce the risk of further glaucomatous damage while minimizing treatment-related burden and adverse effects. Target IOP should be individualized according to the stage and severity of glaucoma, pretreatment IOP, age and life expectancy, rate of disease progression, and other risk factors, and should be reassessed periodically in response to the clinical course of the disease.10

A major challenge in the management of glaucoma is that, although effective treatments are available to lower intraocular pressure (IOP) and reduce the risk of disease progression, no currently available treatment restores lost retinal ganglion cells or reverses established glaucomatous visual-field loss. Consequently, treatment is primarily aimed at preventing or slowing further optic nerve damage through sustained IOP reduction.

Topical ocular hypotensive medications remain an important component of glaucoma management; however, adherence to long-term therapy is frequently suboptimal. Factors contributing to poor adherence include the cost of medications, complex treatment regimens, forgetfulness, difficulty with eye-drop instillation, physical limitations, and adverse effects or intolerance. A systematic review identified complex eye-drop regimens, difficulties with drop administration, and problems with memory and attention among the major barriers to glaucoma medication adherence.11,12 Poor adherence may result in inadequate IOP control and consequently increase the risk of disease progression.

Glaucoma surgery provides an alternative means of achieving sustained IOP reduction and may reduce dependence on daily topical medications. By lowering IOP more consistently, surgical intervention can also reduce the magnitude of diurnal IOP variation. However, despite its potential benefits, acceptance of glaucoma surgery remains an important challenge, particularly in settings where patients may have concerns about the risks, postoperative care, cost, or perceived lack of visual improvement following surgery. In a multi-centre study conducted in Lagos, Nigeria, refusal of glaucoma surgery was relatively common, highlighting the importance of patient education and counselling in the decision-making process.13

Furthermore, patients may be reluctant to undergo incisional glaucoma surgery because they understand that the primary objective is preservation of existing vision rather than improvement of vision, and because of concerns about surgical complications, including the potential for cataract development or progression following some glaucoma procedures. These limitations underscore the need for treatment strategies that provide effective and sustained IOP control while minimizing treatment burden, improving adherence, and addressing patients’ concerns and preferences.13–16

Laser trabeculoplasty may be considered as an initial therapeutic option in appropriately selected patients with ocular hypertension or open-angle glaucoma. The technique has evolved considerably since its introduction, with several laser wavelengths and technologies investigated for treatment of the trabecular meshwork. Argon laser trabeculoplasty (ALT) was the earliest widely adopted approach and became established following the introduction of argon laser treatment for open-angle glaucoma. Subsequently, other laser systems, including the Nd:YAG, diode and frequency-doubled 532-nm Nd:YAG lasers, have been evaluated for trabeculoplasty. Among these, selective laser trabeculoplasty (SLT), which employs a frequency-doubled 532-nm Nd:YAG laser, was developed to selectively target pigmented trabecular meshwork cells while minimizing thermal and structural damage to surrounding tissues.17–20

The development of SLT has broadened the role of laser trabeculoplasty from an adjunctive treatment to a potential first-line therapy. Evidence from randomized clinical trials and systematic reviews indicates that SLT provides intraocular pressure (IOP) reduction comparable to that achieved with topical medications and ALT, while offering the advantages of avoiding issues of medication adherence and reducing exposure to topical drug-related adverse effects.21–23 More recent evidence, including the American Academy of Ophthalmology technology assessment, supports the use of SLT as either a primary intervention, an alternative to topical therapy, or an adjunctive treatment in patients with open-angle glaucoma.24

Laser trabeculoplasty lowers intraocular pressure (IOP) primarily by increasing aqueous humour outflow through the trabecular meshwork. Selective laser trabeculoplasty (SLT) is performed using a Q-switched, frequency-doubled 532-nm neodymium-doped yttrium–aluminium–garnet (Nd:YAG) laser. The short-duration, low-energy laser pulses are preferentially absorbed by melanin within pigmented trabecular meshwork cells, producing selective cellular effects with minimal collateral thermal damage to adjacent non-pigmented tissue. Although the precise mechanism by which SLT enhances aqueous outflow remains incompletely understood, purported mechanisms include cellular and biochemical responses, extracellular matrix remodelling, macrophage recruitment, and increased permeability of the trabecular meshwork and Schlemm’s canal.25–27

The mechanism by which selective laser trabeculoplasty (SLT) lowers intraocular pressure (IOP) is not completely understood and is considered multifactorial. One proposed mechanism involves the recruitment of monocytes and macrophages to the treated trabecular meshwork (TM). SLT may stimulate the release of cytokines and chemotactic factors, including interleukins, which promote monocyte/macrophage recruitment. These cells may enhance aqueous humour outflow through phagocytosis of cellular debris and pigment within the trabecular meshwork, as well as through the release of additional biological mediators that modify trabecular meshwork and Schlemm’s canal function.28,29

The selective action of SLT is attributed to selective photothermolysis, whereby the 532-nm laser energy is preferentially absorbed by melanin-containing cells within the TM. Unlike argon laser trabeculoplasty (ALT), SLT produces minimal coagulative injury and preserves the overall architecture of the trabecular beams. Histopathological studies have demonstrated cracking of intracellular pigment granules with little or no coagulative damage following SLT, in contrast to the crater formation, collagen disruption, and endothelial cell damage associated with ALT.30 Thus, SLT produces substantially less structural damage to the TM, providing a theoretical basis for its repeatability.

The clinical IOP-lowering effect of SLT appears to be broadly comparable to that of ALT. Randomized clinical trials have demonstrated similar reductions in IOP following the two procedures, with SLT showing approximately equivalent efficacy during the first 6 months after treatment.31 A systematic review and meta-analysis likewise found no statistically significant difference in IOP reduction between SLT and ALT at 6 months, 1 year, or most other follow-up time points. These findings suggest that, despite differences in laser wavelength, energy delivery, and the extent of tissue injury, the downstream biological response of the trabecular meshwork that enhances aqueous humour outflow may involve shared pathways of cellular activation, extracellular-matrix remodeling, and increased trabecular outflow facility.29,32,22

Laser trabeculoplasty has been relatively poorly studied in West Africa, and published evidence on its long-term efficacy in the region remains limited. An earlier report from Accra, Ghana, noted that argon laser trabeculoplasty (ALT) appeared to have a limited role in the management of glaucoma in West African patients. In that report, only approximately 20–30% of treated eyes achieved satisfactory IOP control at one year, despite the use of adjunctive medical therapy.33 This observation highlighted the need for further evaluation of alternative laser trabeculoplasty techniques that might provide more sustained IOP control with less dependence on topical medication.

To the best of our knowledge, the present study represents the first reported evaluation in Nigeria of frequency-doubled 532-nm neodymium-doped yttrium aluminium garnet (Nd:YAG) laser trabeculoplasty. Preliminary findings from this study were presented at the World Glaucoma Congress held in Boston in 2009 and published in the Congress abstract book (2009, p. 264, abstract P433). The study was undertaken in the context of the substantial burden of glaucoma in West Africa and the challenges associated with long-term adherence to topical glaucoma medications. The potential value of laser trabeculoplasty in this setting lies in its ability to enhance aqueous humour outflow while reducing reliance on daily topical therapy.34,35

The aim of this study was to evaluate the long-term effectiveness of frequency-doubled 532-nm Nd:YAG laser trabeculoplasty in achieving and maintaining a target IOP of <18 mmHg and reducing the number of topical glaucoma medications required in patients with inadequately controlled glaucoma.

Materials and Method

This retrospective study involved a review of previously collected clinical data from patients who underwent laser trabeculoplasty. Institutional Review Board (IRB) approval was not required, as determined by the Eye Foundation Hospital Research Ethics Committee, because the study involved the analysis of existing clinical data without direct patient participation or access to identifiable patient information. Accordingly, the study was considered exempt from formal ethical review, and the principles of the Declaration of Helsinki were deemed not applicable.

Study design and patient selection

This was a retrospective review of the medical records of patients who underwent laser trabeculoplasty for intraocular pressure (IOP) control at Eye Foundation Hospital, Ikeja, a public–private tertiary healthcare institution in southwestern Nigeria, between November 2004 and August 2005. The study included 53 eyes of 42 patients with glaucoma who underwent laser trabeculoplasty because adequate IOP control had not been achieved with medical therapy.

Prior to laser treatment, all patients underwent gonioscopic assessment of the anterior chamber angle. Particular attention was paid to the angle configuration, iris curvature, and degree of trabecular meshwork pigmentation.

Patients were eligible for laser trabeculoplasty if they had primary open-angle glaucoma with poorly controlled or substantially fluctuating IOP despite medical therapy, and in whom the target IOP had not been achieved. Patients with peripheral anterior synechiae, iris rubeosis, corneal oedema, or inadequate visualization of the anterior chamber angle for any other reason were excluded.

The highest recorded pre-laser intraocular pressure (IOP) and subsequent IOP measurements at 1, 6, 12, 18, 24, 30, and 36 months following laser trabeculoplasty were retrieved from the patients’ medical records. The number of antiglaucoma medications prescribed before laser treatment and during follow-up was also recorded. Visual acuity, assessed using a Snellen chart, was documented at baseline and at subsequent follow-up visits, where available. Data were analysed using Epi Info, Version 8.

Treatment procedure

Immediately before the procedure, pilocarpine 2% was instilled to induce pupillary constriction. The procedures were performed using a frequency-doubled Nd:YAG 532-nm laser (Eyelight). The laser parameters included a 50-µm spot size, 0.2-second duration, and power ranging from 250 to 400 mW. Laser treatment was applied over 360° of the trabecular meshwork, commencing at the 12 o’clock position and proceeding clockwise, with approximately 80–100 laser applications. Trabecular meshwork blanching was used as an endpoint indicating adequate laser application.

Postoperatively, patients received oral acetazolamide 250 mg twice daily for one day and a topical corticosteroid every 8 hours for one week. Patients continued their pre-existing antiglaucoma medications for one month following laser trabeculoplasty, after which a gradual trial withdrawal of medications was undertaken where clinically appropriate. The general target IOP was below 18 mmHg.

Results

A total of 53 eyes from 42 patients were included in the analysis, comprising 40 male eyes and 13 female eyes. The mean age was 65 years among males and 62 years among females. Although the difference in age was statistically significant (P = 0.006), the observed difference in mean age was relatively small and is unlikely, in isolation, to have had a major influence on the treatment response.

Table 1. Mean changes in IOP and number of medications by type of eye

VariableType of eyeStudent’s t statisticp
Male eyes
(n = 40)
Female eyes
(n = 13)
Change in IOP6.73 ± 5.758.00 ± 6.270.680.50
Percentage change in IOP30.93 ± 26.2634.08 ± 20.930.390.70
Change in number of medications0.15 ± 0.620.00 ± 0.580.770.45
Right eye
(n = 26)
Left eye
(n = 27)
Change in IOP7.77 ± 5.096.33 ± 6.500.890.38
Percentage change in IOP36.79 ± 18.2026.80 ± 29.511.480.15
Change in number of medications0.04 ± 0.450.19± 0.740.870.39

Table 2 demonstrates the effect of laser trabeculoplasty on intraocular pressure (IOP) and the number of antiglaucoma medications used by the 53 eyes included in the study.

Table 2. Mean changes in IOP and number of medication pre and post operation

VariableMeanSD
Intraocular pressure (n = 53)
Pre operation18.595.97
Post operation11.552.45
Change (reduction)7.045.84
Percentage change (reduction)31.7024.90
Paired t statistic = 8.76, df = 52, p = 0.00
Number of medication (n = 53)
Pre operation1.720.79
Post operation1.000
Change0.110.61
Paired t statistic = 1.35, df = 52, p > 0.05

The mean preoperative IOP was 18.59 ± 5.97 mmHg, which decreased to 11.55 ± 2.45 mmHg following laser trabeculoplasty. This represents a mean absolute reduction of 7.04 ± 5.84 mmHg, corresponding to a 31.70% ± 24.90% reduction in IOP. The paired t-test demonstrated a statistically significant difference between the pre- and post-treatment IOP values (t = 8.76, df = 52, P < 0.001). This indicates that laser trabeculoplasty produced a significant reduction in IOP in the study population.

The relatively low post-treatment standard deviation (2.45) compared with the pre-treatment standard deviation (5.97) suggests that IOP values became less variable following treatment. This may indicate a more consistent level of IOP control after laser trabeculoplasty.

The mean number of antiglaucoma medications decreased from 1.72 ± 0.79 before treatment to 1.00 ± 0 after treatment. Although this represents a numerical reduction in medication burden, the reported change was not statistically significant (paired t = 1.35, df = 52, P > 0.05). Thus, despite the significant reduction in IOP, the study did not demonstrate a statistically significant reduction in the number of medications required

In Table 2, change in the number of medications was considered and it was found not to be significant, Paired t stastistic = 1.35, P>0.05

The changes in medications were done at different times on follow up, what determined these was target IOP at 18mmHg. 17 eyes 32.1% were maintained on their previous medications 24 eyes, 45.3% had their medications reduced 11eyes, 20.8% had their medications increased 1 eye 1.9% had no medications before and after laser trabeculoplasty

Table 3 compares preoperative and postoperative intraocular pressure (IOP) using 18 mmHg as the target IOP. The table shows a clear shift toward better IOP control following laser trabeculoplasty.

Table 3. Intraocular pressure (pre and post operation)

Pre operation IOP (mmHg)Post operation IOP (mmHg)
<18≥18Total
<1823 (100)0 (0)23
≥ 1827 (90.0)3 (10.0)30
Total50 (94.3)3 (5.7)53
McNemar χ2 = 25.04, p 0.00

Eyes with preoperative IOP <18 mmHg

There were 23 eyes with a preoperative IOP below 18 mmHg. All 23 eyes (100%) remained below 18 mmHg after treatment, and none had a postoperative IOP ≥18 mmHg.

This indicates that eyes that were already below the target IOP before treatment generally maintained satisfactory IOP control following laser trabeculoplasty.

Eyes with preoperative IOP ≥18 mmHg

There were 30 eyes with a preoperative IOP of 18 mmHg or higher. 27 eyes (90.0%) achieved a postoperative IOP <18 mmHg. Only 3 eyes (10.0%) remained at or above 18 mmHg after treatment. This is an important finding because it demonstrates that 90% of eyes with initially elevated IOP were successfully brought below the predefined target of 18 mmHg following laser trabeculoplasty.

Overall outcome

Overall, 50 of the 53 eyes (94.3%) had a postoperative IOP <18 mmHg, while only 3 eyes (5.7%) had an IOP ≥18 mmHg.

The McNemar test showed a χ² value of 25.04 with P <0.001, demonstrating a statistically significant change in the proportion of eyes achieving the target IOP before versus after laser trabeculoplasty.

Table 4. Mean of difference in IOP post laser

Difference (Post laser)Mean of difference in IOP (mmHg)Paired tp
Pre laser & I month11.0 ± 7.610.94< 0.05*
1 month & 6 months2.3 ± 6.42.65< 0.05*
6 months & 12 months0.8 ± 5.91.09> 0.05
12 months & 18 months2.2 ± 7.62.14< 0.05*
18 months & 24 months2.4 ± 5.23.50< 0.05*
24 months & 30 months0.5 ± 3.41.09> 0.05
30 months & 36 months1.4 ± 6.81.50> 0.05

*Significant

The table demonstrates that the greatest change in IOP occurred during the first month after laser trabeculoplasty, with a mean difference of 11.0 mmHg. Thereafter, the magnitude of change was substantially smaller and varied across the follow-up periods.

Statistically significant changes occurred during Pre-laser to 1 month, 1to 6 months, 12 to 18 months and 18 to 24 months. No statistically significant changes occurred during 6 to12 months, 24 to 30 months and 30 to 36 months.

The pattern suggests that laser trabeculoplasty produced a marked early reduction in IOP, followed by periods of relative stability interspersed with statistically significant changes during longer-term follow-up.

Figure 1 shows the mean IOP before trabeculoplasty and after trabeculoplasty over a period of 36 months. It demonstrates a pronounced reduction in mean IOP following trabeculoplasty. Mean IOP was consistently maintained below 18mmHg, it is important to say that patients were lost at different stages of follow up.

Figure 1. Graph of post trabeculoplasty mean IOP over time

Figure 2 demonstrates the pattern of change in intraocular pressure (IOP) following laser trabeculoplasty. The greatest mean reduction in IOP occurred during the early post-laser period, with a mean difference of 11.0 ± 7.6 mmHg between the pre-laser and 1month measurements. This represents a substantial initial response to laser treatment and suggests that the intervention produced its most pronounced IOP-lowering effect during the early follow-up period.

Figure 2. Mean of difference in IOP over time

Table 3 and Figure 2 demonstrate the mean changes in intraocular pressure (IOP) over the follow-up period. Paired t-test analysis showed statistically significant differences in IOP between pre-laser and 1 month, 1 and 6 months, 12 and 18 months, and 18 and 24 months, with mean differences of 11.0 ± 7.6, 2.3 ± 6.4, 7.6, and 5.2 mmHg, respectively (P < 0.05). A statistically significant improvement in visual acuity was also observed following laser trabeculoplasty (P = 0.0001).

Discussion

Agarwal et al. specifically evaluated frequency-doubled Nd:YAG laser trabeculoplasty (YLT) in patients with primary open-angle glaucoma. In this prospective comparative study, 52 eyes of 35 patients were treated with either diode laser trabeculoplasty (25 eyes) or frequency-doubled Nd:YAG laser trabeculoplasty (27 eyes). Baseline IOP was approximately 25 mmHg in both groups. Following YLT, mean IOP decreased to 18.6 ± 1.52 mmHg at 12 months, representing an approximate 26.6% reduction from baseline. The reduction was statistically significant at 3, 6, 9 and 12 months. The reported success rate was 92.6% at 12 months, with success defined as IOP <21 mmHg without medication, or a reduction in medication without progression of disc or visual-field changes. YLT was found to be as effective as diode laser trabeculoplasty.36 The finding in our cohort that 90% of eyes with an initially elevated IOP achieved <18 mmHg is therefore clinically relevant.

Guzey et al. also demonstrated substantial efficacy of frequency-doubled Nd:YAG trabeculoplasty. In 36 eyes with POAG, discontinuation of medical therapy followed by laser treatment resulted in a 36.4% reduction in mean IOP, a 29.8% reduction in peak IOP, and a 50.0% reduction in the diurnal IOP range at 12 weeks.19 Figure 1 illustrates the trend in mean intraocular pressure (IOP) following trabeculoplasty over the follow-up period. The baseline mean IOP was 22.0 ± 6.4 mmHg, which decreased substantially after treatment and remained relatively stable during follow-up.

Baseline Mean IOP was 22.0 ± 6.4 mmHg. Following trabeculoplasty, the mean IOP fell to approximately 12.3 ± 3.1 mmHg, representing a reduction of about 44% from baseline. The IOP subsequently remained within a relatively narrow range, approximately 11.2–12.7 mmHg, during the intermediate follow-up visits. The lowest recorded mean IOP was 11.2 ± 2.5 mmHg, corresponding to an approximate 49% reduction from baseline. At the final follow-up, the mean IOP was approximately 12.3 ± 7.5 mmHg, still about 44% below the baseline value. The greater reduction in mean IOP observed in this study, compared with the findings of Guzey et al., may be attributed to the continuation of IOP-lowering medications in the present study, whereas medications were discontinued in the study by Guzey et al. These results are broadly consistent with the efficacy of laser trabeculoplasty in lowering IOP.

Evidence showed that conventional frequency-doubled Nd:YAG (YLT) trabeculoplasty can achieve an IOP-lowering effect comparable to argon laser trabeculoplasty. In a bilateral comparative study, IOP reduction at 90 days was approximately 24.5% with YLT versus 32.9% with ALT, with no statistically significant difference between the treatments. The inflammatory response was less pronounced and occurred earlier after YLT.36 However, conventional frequency-doubled Nd:YAG (YLT) should be distinguished from selective laser trabeculoplasty (SLT), although both use a 532-nm frequency-doubled Nd:YAG laser. YLT should not be equated automatically with SLT.

Table 5. Comparison relevant to this study is shown in the table below:

Conventional frequency-doubled Nd:YAG (YLT)Selective Laser Trabeculoplasty (SLT)
Wavelength532 nm532 nm
Laser sourceFrequency-doubled Nd:YAGFrequency-doubled Nd:YAG
Pulse characteristicsLonger/higher-energy depending on techniqueQ-switched, ~3 ns
Spot sizeVariable, usually 50 microns400 microns
MechanismPredominantly thermal/coagulative at conventional settingsSelective photothermolysis
TargetTrabecular meshworkPigmented TM cells
Structural TM damageGreaterMinimal
IOP reductionApproximately 25-35% in published studiesCommonly ~20-30%, depending on baseline IOP and population
Repeat treatmentPotentially limited by thermal damageMore readily repeatable
Historical roleAlternative to ALTModern laser trabeculoplasty

The prospect of reducing intraocular pressure (IOP) with laser treatment without entering the anterior chamber was first described by Krasnov in 1973. This concept subsequently evolved into laser trabeculoplasty, initially with argon laser trabeculoplasty (ALT) and later with selective laser trabeculoplasty (SLT). SLT was introduced as a less destructive form of laser trabeculoplasty, using selective photothermolysis of pigmented trabecular meshwork cells while producing minimal structural damage to the surrounding tissue. Since its introduction, SLT has been evaluated both as an initial treatment and as an adjunct to topical glaucoma therapy.

The overall IOP reduction of 31.70% observed in the present study (Table 2) is comparable with reductions reported in previous studies of laser trabeculoplasty, including SLT. Latina et al. demonstrated significant IOP reduction following SLT in their multicentre pilot study, establishing the efficacy of selective laser treatment of the trabecular meshwork in lowering IOP.37 Similarly, McIlraith et al. reported that SLT was effective when used both as initial and adjunctive treatment in patients with open-angle glaucoma, supporting its role as an alternative or complementary treatment to topical medication.38 The percentage IOP reduction in the present study was also slightly higher than that reported in the latanoprost-treated group in the randomized prospective study by Nagar et al.39 Nagar et al. compared SLT with latanoprost in patients with ocular hypertension and open-angle glaucoma and demonstrated substantial and comparable IOP-lowering effects with both treatment modalities. The 31.70% reduction observed in the present study therefore compares favourably with the reduction achieved with latanoprost in that study. However, this difference should be interpreted cautiously because of differences in baseline IOP, patient characteristics, treatment protocols and follow-up periods between the studies. It would therefore be inappropriate to conclude that laser trabeculoplasty is superior to latanoprost solely on the basis of the observed percentage reduction.

An important finding in the present study was that laser treatment permitted maintenance of an IOP of less than 18 mmHg with a reduction in the number of antiglaucoma medications required. (Table 3). This finding is clinically relevant because the contemporary role of laser trabeculoplasty extends beyond simply providing additional IOP reduction in patients inadequately controlled on medication. SLT is increasingly regarded as a medication-sparing treatment, with the potential to reduce the patient’s dependence on topical therapy while maintaining target IOP.

The concept of SLT has therefore evolved from being predominantly an adjunctive treatment to being considered a potential first-line treatment for appropriately selected patients with ocular hypertension and open-angle glaucoma. This is supported by subsequent evidence, particularly the LiGHT trial, which demonstrated that primary SLT can achieve effective IOP control while reducing the need for topical glaucoma medications.40 The medication-sparing effect is particularly important in clinical settings where the cost of lifelong topical therapy, challenges with medication adherence and availability, and ocular-surface intolerance may compromise long-term treatment outcomes.41–43

The findings of the present study are therefore consistent with the broader evolution of laser trabeculoplasty in glaucoma management. Although the laser technique used in this study was frequency-doubled Nd:YAG 532-nm laser trabeculoplasty rather than SLT, the substantial IOP reduction observed demonstrates the effectiveness of laser treatment of the trabecular meshwork. The results also support the concept that laser trabeculoplasty can reduce medication burden while maintaining clinically desirable IOP levels.

Overall, the 31.70% reduction in IOP observed in this study compares favourably with previous reports of laser trabeculoplasty and with the IOP-lowering effect of topical latanoprost reported by Nagar et al. The ability to maintain IOP below 18 mmHg with fewer medications further suggests that laser trabeculoplasty may have an important adjunctive and medication-sparing role, while contemporary evidence supports an expanding role for SLT as a primary treatment option in suitable patients with open-angle glaucoma and ocular hypertension.

The medication-sparing effect observed in the present study compares favourably with the findings of Pollack and Robin, who evaluated the effect of argon laser trabeculoplasty (ALT) on medical control of primary open-angle glaucoma. In their prospective study, patients who were inadequately controlled on medical therapy underwent ALT with the objective of maintaining an IOP of less than 22 mmHg using fewer medications than were required before laser treatment. Following trabeculoplasty, approximately one-third of patients required no medication, 39% required fewer medications, while 28% required the same medication regimen to maintain IOP control.44 In comparison, 45.3% of patients in the present study required fewer medications, while 32.1% required the same medication regimen after laser trabeculoplasty. (Table 2)

The greater proportion of patients requiring fewer medications in the present study suggests a substantial medication-sparing effect of laser trabeculoplasty. Pollack and Robin also demonstrated a marked reduction in the need for specific medications, with six of nine patients previously receiving carbonic anhydrase inhibitors no longer requiring these agents after ALT. Similarly, in the present study, none of the patients required a carbonic anhydrase inhibitor following trabeculoplasty, suggesting an important reduction in treatment burden. These findings support the ability of laser trabeculoplasty to reduce dependence on topical and systemic antiglaucoma medications in appropriately selected patients.

However, the proportion of patients requiring continued or additional medication in the present study should be interpreted in the context of the more stringent target IOP of less than 18 mmHg used in this study compared with the target of less than 22 mmHg used by Pollack and Robin. In the present study, 20.8% of patients required additional medication during follow-up in an effort to maintain IOP below 18 mmHg. The higher treatment intensity may therefore reflect the lower target IOP rather than inadequate efficacy of laser trabeculoplasty. This distinction is clinically important because the degree of medication reduction achievable after laser treatment is influenced not only by the magnitude of the laser-induced IOP reduction but also by the target pressure established for an individual patient.

The findings also illustrate the evolution of the role of laser trabeculoplasty in glaucoma management. The earlier studies by Pollack and Robin demonstrated that ALT could reduce the medication burden in patients with medically controlled open-angle glaucoma, although most patients continued to require some treatment. Their subsequent study similarly found that, when medication reduction was attempted to maintain an IOP below 22 mmHg, 82% of eyes still required some medication, while 18% achieved control without further medical therapy.

Thus, the present study demonstrates that laser trabeculoplasty can provide meaningful reduction in medication burden while maintaining a relatively low target IOP. The fact that nearly half of the patients required fewer medications after treatment, together with the complete discontinuation of carbonic anhydrase inhibitors, supports the medication-sparing role of laser trabeculoplasty. At the same time, the need for additional medication in 20.8% of patients highlights that laser treatment should not necessarily be regarded as a replacement for pharmacological therapy in every patient, particularly when a stringent IOP target is required. Rather, its value lies in achieving adequate IOP control with the lowest feasible medication burden, which is particularly relevant in long-term glaucoma management.

Table 4 demonstrated statistically significant differences in IOP between baseline and 1 month, between 1 and 6 months, between 12 and 18 months, and between 18 and 24 months following laser trabeculoplasty. There was a marked reduction in mean IOP from 22.0 ± 6.4 mmHg at baseline to 12.3 ± 3.1 mmHg at 1 month, 11.9 ± 2.3 mmHg at 6 months, 12.2 ± 2.5 mmHg at 12 months, 12.7 ± 3.0 mmHg at 18 months and 11.2 ± 2.5 mmHg at 24 months (Figure 1). The reduction was statistically significant (paired t = 8.76, df = 52, p < 0.001), demonstrating a substantial and sustained IOP-lowering effect of laser trabeculoplasty over the 36-month follow-up period.

The sustained IOP reduction observed in this study is consistent with previous reports demonstrating the long-term efficacy of laser trabeculoplasty. Sicáková and Výborný reported sustained IOP-lowering efficacy following SLT over three years of follow-up, supporting the durability of laser treatment in glaucoma management.13 Similarly, long-term studies of ALT have demonstrated that the IOP-lowering effect can persist for several years following treatment.18 These findings suggest that the beneficial effect of laser trabeculoplasty is not limited to the immediate post-treatment period but may provide clinically meaningful IOP control over the longer term.

Although SLT and ALT differ in their laser-tissue interaction, studies have demonstrated that SLT can provide effective IOP reduction comparable to conventional laser trabeculoplasty. The three-year follow-up reported by Sicáková and Výborný further supports the sustained effectiveness of SLT.47 The present findings are therefore consistent with the broader evidence that laser treatment directed at the trabecular meshwork can provide sustained IOP reduction.

In contrast to the significant reduction in IOP, the change in the number of antiglaucoma medications was not statistically significant (paired t = 1.35, df = 52, p > 0.05) (Table 2). This finding should, however, be interpreted in the context of the individual target IOP and the adjunctive use of medications when required. Martow et al. demonstrated that the need for adjunctive medical therapy following SLT varies among patients and that clinical characteristics can help predict the likelihood of requiring additional treatment.45 Thus, the absence of a statistically significant overall reduction in medication use in the present study does not necessarily imply a lack of medication-sparing benefit at the individual patient level.

Careful gonioscopic assessment is essential before laser trabeculoplasty to ensure adequate visualization and access to the trabecular meshwork. This is particularly important in eyes with heavily pigmented angles. Ritch and colleagues demonstrated the effectiveness of argon laser trabeculoplasty in pigmentary glaucoma, in which marked trabecular pigmentation permits readily visible laser uptake but may also increase the response to treatment and the risk of an IOP spike.46 In the present study, blanching of the laser spots was readily observed in eyes with pigmented trabecular meshwork.

In some eyes, primary iridoplasty was performed to enhance access to the trabecular meshwork when the angle structures were inadequately exposed, particularly in cases of appositional angle. This highlights the importance of thorough gonioscopic assessment and appropriate angle preparation to achieve adequate trabecular meshwork exposure before laser treatment.

There was no statistically significant difference in IOP response according to laterality of the treated eye or sex. These findings suggest that neither right versus left eye nor sex was a significant determinant of treatment response in this study. Nevertheless, these negative findings should be interpreted cautiously, particularly in view of the relatively small sample size.

A significant improvement in visual acuity was observed following laser trabeculoplasty in the present study (p = 0.0001). Since the primary objective of laser trabeculoplasty is IOP reduction rather than visual rehabilitation, this improvement should be interpreted cautiously. It may reflect improved visual function associated with better IOP control or other factors unrelated directly to the laser treatment. Importantly, the primary evidence supporting laser trabeculoplasty relates to its ability to reduce IOP and delay the need for more invasive glaucoma interventions rather than to directly improve visual acuity.

The long-term significance of achieving sustained IOP reduction is particularly relevant in glaucoma, where preservation of visual function depends on adequate and sustained control of IOP. The Advanced Glaucoma Intervention Study demonstrated the importance of maintaining adequate IOP control in reducing the risk of glaucomatous progression, with treatment outcomes also varying according to race.47 Earlier studies have also demonstrated that laser trabeculoplasty can provide long-term IOP control and may delay or reduce the need for incisional surgery in selected patients.48–49 The present study demonstrates a substantial and sustained reduction in IOP following frequency-doubled Nd:YAG 532-nm laser trabeculoplasty, with mean IOP remaining substantially below baseline throughout the 36-month follow-up period. Although the overall reduction in medication use was not statistically significant, the treatment provided effective IOP control and, in individual patients, permitted reduction in medication requirements. These findings support the role of laser trabeculoplasty as an effective component of glaucoma management and are consistent with the broader contemporary concept of laser treatment as a means of achieving sustained IOP control while potentially reducing reliance on long-term topical therapy.

Conclusion

Frequency-doubled Nd:YAG 532-nm laser trabeculoplasty achieved a significant and sustained reduction in intraocular pressure over 36 months of follow-up. Although the overall reduction in antiglaucoma medication use was not statistically significant, nearly half of the patients required fewer medications following treatment. These findings suggest that frequency-doubled Nd:YAG laser trabeculoplasty can provide sustained IOP control and may reduce medication requirements in selected patients with glaucoma. Careful gonioscopic assessment and adequate visualization of the trabecular meshwork are essential for appropriate patient selection and effective treatment.

References

  1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013.
  2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. doi:10.1136/bjo.2005.081224.
  3. Kyari F, Abdull MM, Bastawrous A, Gilbert CE, Faal H. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors. Middle East Afr J Ophthalmol. 2013 Apr-Jun;20(2):111-25. doi: 10.4103/0974-9233.110605.
  4. Cook C, Foster P. Epidemiology of glaucoma: what’s new? Can J Ophthalmol. 2012;47(3):223-226. doi:10.1016/j.jcjo.2012.02.003.
  5. Rudnicka AR, et al. Global variations and time trends in the prevalence of primary open-angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100:86-93.
  6. Soh Z, et al. The global extent of undetected glaucoma in adults: a systematic review and meta-analysis. Ophthalmology. 2021;128(10):1393-1404. doi:10.1016/j.ophtha.2021.04.009.
  7. Abdull MM, Sivasubramaniam S, Murthy GVS, et al. Causes of blindness and visual impairment in Nigeria: the Nigeria National Blindness and Visual Impairment Survey. Investigative Ophthalmology & Visual Science. 2009;50(5):2075–2079.
  8. Kyari F, Entekume G, Rabiu M, et al. A population-based survey of the prevalence and types of glaucoma in Nigeria: results from the Nigeria National Blindness and Visual Impairment Survey. BMC Ophthalmology. 2015;15:176.
  9. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 6th ed. European Glaucoma Society, 2025.
  10. Konstantakopoulou E, Gazzard G, Garway-Heath D, et al. Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension. JAMA Ophthalmol. 2025;143(4):295–302. doi:10.1001/jamaophthalmol.2024.6492
  11. Bott D, Subramanian A, Edgar D, Lawrenson JG, Campbell P. Barriers and enablers to medication adherence in glaucoma: a systematic review of modifiable factors using the Theoretical Domains Framework. Ophthalmic Physiol Opt. 2024;44(1):96–114. doi:10.1111/opo.13245.
  12. Moore SG, et al. Factors affecting glaucoma medication adherence and interventions to improve adherence: a narrative review. Ophthalmol Ther. 2023;12. doi:10.1007/s40123-023-00797-8.
  13. Adekoya BJ, Akinsola FB, Balogun BG, Balogun MM, Ibidapo OO. Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria. Middle East Afr J Ophthalmol. 2013;20(2):168–173. doi:10.4103/0974-9233.110612.
  14. Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence. 2021;15:1477–1489. doi:10.2147/PPA.S264926.
  15. Anad N, Mielke C, Dawda VK. Trabeculectomy outcomes in advanced glaucoma in Nigeria. Eye 2001;15:274–8.
  16. Peter R Egbert. Glaucoma in West Africa : A neglected problem. Br J Ophthalmol. 2002; 86(2):131-2.
  17. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979;97(2):319-322.
  18. McHugh D, Marshall J, Ffytche TJ, Hamilton PA, Raven A. Diode laser trabeculoplasty (DLT) for primary open-angle glaucoma and ocular hypertension. Br J Ophthalmol. 1990;74(12):743-747.
  19. Guzey M, Arslan O, Tamcelik N, Satici A. Effects of frequency-doubled Nd:YAG laser trabeculoplasty on diurnal intraocular pressure variations in primary open-angle glaucoma. Ophthalmologica. 1999;213(4):214-218.
  20. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60:359-371.
  21. Waisbourd M, Katz LJ. Selective laser trabeculoplasty as a first-line therapy: a review. Can J Ophthalmol. 2014;49(6):519-522. doi:10.1016/j.jcjo.2014.10.003.
  22. Wong MO, Lee JW, Choy BN, Chan JC, Lai JS. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015;60(1):36-50.
  23. Landers J. Selective laser trabeculoplasty: a review. Clin Exp Ophthalmol. 2021;49(9):1102-1110. doi:10.1111/ceo.13979.
  24. Takusagawa HL, Hoguet A, Sit AJ, Rosdahl JA, Chopra V, Ou Y, Richter G, Kim SJ, WuDunn D. Selective laser trabeculoplasty for the treatment of glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2024 Jan 1;131(1):37-47..
  25. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773-779.
  26. Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008;17(6):497-502.
  27. Chen YF, Zeng W. Mechanism of selective laser trabeculoplasty: a systematic review. Int J Ophthalmol. 2024;17(4):694-702.
  28. Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Rouse B, McCartney MD. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells interact with monocytes. Invest Ophthalmol Vis Sci. 2013;54:7830-7839.
  29. Kagan DB, Gorfinkel NS, Hutnik CML. Mechanisms of selective laser trabeculoplasty: a review. Clin Exp Ophthalmol. 2014;42(7):675-681.
  30. Cvenkel B, Hvala A, Drnovsek-Olup B, Gale N. Acute ultrastructural changes of the trabecular meshwork after selective laser trabeculoplasty and low-power argon laser trabeculoplasty. Lasers Surg Med. 2003;33(3):204-208.
  31. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a one-year randomised clinical trial. Br J Ophthalmol.2006;90:1490-1494.
  32. Garg A, Gazzard G. Selective laser trabeculoplasty: past, present, and future. Eye (Lond). 2018;32:863-876.
  33. Lewallen S, Courtright P. Glaucoma in West Africa: a neglected problem. Br J Ophthalmol. 2001;85(2):131-132.
  34. Abdelrahman AM. Noninvasive glaucoma procedures: current options and future innovations. Middle East Afr J Ophthalmol. 2015;22(2):162-169.
  35. World Glaucoma Congress. World Glaucoma Congress 2009 Abstract Book. Published 2009.
  36. Agarwal HC, Poovali S, Sihota R, Dada T. Comparative evaluation of diode laser trabeculoplasty vs frequency-doubled Nd:YAG laser trabeculoplasty in primary open-angle glaucoma. Eye (Lond). 2006;20(12):1352-1356.
  37. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Selective laser trabeculoplasty: a multicenter pilot clinical study. Ophthalmology. 1998;105:2082–2088.
  38. McIlraith I, Strasfeld M, Coley G, Hutnik CML. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006;15(2):124–130.
  39. Nagar M, Ogunyomade A, O’Brart DPS, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open-angle glaucoma. Br J Ophthalmol. 2005;89:1413–1417.
  40. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505–1516.
  41. Vélez-Gómez MC, Vásquez-Trespalacios EM. Adherence to topical treatment of glaucoma, risk and protective factors: A review. Archivos de la Sociedad Española de Oftalmología (English Edition). 2018 Feb 1;93(2):87-92.
  42. Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: a narrative review. Ophthalmology and Therapy. 2023 Dec;12(6):2863-80.
  43. Aribaba OT, Adenekan OA, Alabi AS, Aina MT, Anunobi CC, Onakoya AO. Clinico-cytological analysis of conjunctiva and ocular surface symptoms of patients on topical anti-glaucoma medications attending Lagos University Teaching Hospital, Lagos, Nigeria: A Case–Control Study. Nigerian Postgraduate Medical Journal. 2023 Jul 1;30(3):240-9.
  44. Pollack IP, Robin AL Argon laser trabeculoplasty: its effect on medical control of open-angle glaucoma. Ophthalmic Surg.1982 Aug;13(8):637-43.
  45. Sicáková S, Výborný P. [Selective laser trabeculoplasty in glaucoma treatment--results during three years follow-up]. Cesk Slov Oftalmol. 2010 Nov;66(5):204
  46. Martow E, Hutnik CM, Mao A. SLT and adjunctive medical therapy: a prediction rule analysis. J Glaucoma. 2011 Apr-May;20(4):266-70.
  47. Ritch R, Liebmann J, et al Argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmol 1993;100:909-13
  48. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), IV: Comparison of treatment outcomes within race: seven –year results. Ophthalmol 1998;105;1146-64.
  49. Shingleton BJ,Richter CU. Dhama SK et al. Long term efficacy of argon laser trabeculoplasty: a ten year follow -up study.Ophthalmol 1993,;100;1324-9.
  50. Schhwartz AL. Whitten ME, Bleiman B, Martin D. Surgery in the uncontrolled phakic open glaucoma. Ophthal 1981; 88:203-212.

Article information

Authors

How to cite

Ogunro, A., A, H., et al., 2026. Review of Intraocular Pressure Control with Adjunctive Laser Trabeculoplasty in a Black Population- Nigeria (West Africa). Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0594

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
45

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.